Axsome Therapeutics - AXSM Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axsome Therapeutics in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AXSM shares.
View AXSM analyst ratings or view top-rated stocks.

8 brokerages have issued 12-month price objectives for Axsome Therapeutics' shares. Their AXSM share price forecasts range from $54.00 to $210.00. On average, they anticipate the company's stock price to reach $109.00 in the next twelve months. This suggests a possible upside of 136.5% from the stock's current price.
View analysts price targets for AXSM or view top-rated stocks among Wall Street analysts.

Axsome Therapeutics' stock was trading at $37.78 at the beginning of 2022. Since then, AXSM stock has increased by 22.0% and is now trading at $46.08.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our AXSM earnings forecast.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) announced its quarterly earnings results on Tuesday, August, 9th. The company reported ($1.06) earnings per share for the quarter, beating the consensus estimate of ($1.19) by $0.13. The company earned $8.82 million during the quarter, compared to analyst estimates of $9.59 million. During the same quarter in the prior year, the company earned ($0.86) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axsome Therapeutics investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Dicerna Pharmaceuticals (DRNA), Amarin (AMRN), Sarepta Therapeutics (SRPT), Micron Technology (MU), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and Bristol-Myers Squibb (BMY).

(AXSM) raised $52 million in an initial public offering on Thursday, November 19th 2015. The company issued 4,300,000 shares at a price of $11.00-$13.00 per share. Ladenburg Thalmann and Cantor Fitzgerald & Co. served as the underwriters for the IPO and Brean Capital was co-manager.

Axsome Therapeutics trades on the NASDAQ under the ticker symbol "AXSM."

Shares of AXSM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXSM stock can currently be purchased for approximately $46.08.

Axsome Therapeutics (NASDAQ:AXSM) has a market capitalization of $1.79 billion. The company earns $-130,400,000.00 in net income (profit) each year or ($3.92) on an earnings per share basis.

The company employs 108 workers across the globe.

Axsome Therapeutics' mailing address is 200 BROADWAY 3RD FLOOR, NEW YORK NY, 10038. The official website for the company is axsome.com. The company can be reached via phone at (212) 332-3241 or via fax at 212-320-0245.